Compare AbbVie Inc (ABBV) vs Core and Main Inc (CNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Core and Main Inc — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Core and Main Inc trades at $46.73 (market cap $8.67B). The key difference: AbbVie Inc is far larger — about 50.5× Core and Main Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Core and Main Inc pays none. Which is the better fit depends on your goals.
| ABBV | CNM | |
|---|---|---|
Market Cap | $438.19B | $8.67B |
Sector | Health | Technology |
52-Week High | $263.58 | $66.98 |
52-Week Low | $197.38 | $42.37 |
Enterprise Value | $502.45B | $10.96B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
Core & Main (CNM) trades at $46.55, up 2.33% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 23.73% ROE and 5.87% net margin, supported by resilient municipal demand. Recent news highlights institutional activity, including CalSTRS increasing its stake by 22.3% in Q1 2026 (Defense World, 2026-08-04).
The outlook is mixed: analyst consensus leans bullish with 57% buy ratings, but technical indicators suggest near-term pressure. Key risks include high debt levels and residential market weakness. Upside hinges on margin expansion and FY26 revenue guidance of $7.8–7.9B (Business Wire, 2026-06-25).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →
